IIEF Domains | VigRX Plus | Placebo | ||||||
---|---|---|---|---|---|---|---|---|
 | Baseline | EoT | Change | 95%CI | Baseline | EoT | Change | 95%CI |
EF,Q1-5,15 | 16.08 (2.87) | 25.08 (4.56)* | 9 (4.95) | 7.40,10.60 | 15.86 (3.24) | 16.47 (4.25) | 0.61(2.43) | −0.21,1.43 |
Q1 | 3.38 (0.67) | 4.64 (0.67) | 1.26 (0.88) | 0.98,1.54 | 3.33 (0.53) | 3.38 (0.77) | 0.06 (0.58) | −0.14,0.25 |
Q2 | 2.71(0.65) | 4.17 (0.82) | 1.46 (0.94) | 1.16,1.76 | 2.66 (0.63) | 2.80 (0.75) | 0.14 (0.42) | −0.0,0.28 |
Q3 | 2.69 (0.57) | 4.12 (0.80) | 1.43 (0.85) | 1.15,1.70 | 2.63 (0.59) | 2.75 (0.69) | 0.11(0.46) | −0.05,0.26 |
Q4 | 2.56 (0.50) | 4.02 (0.81) | 1.46 (0.91) | 1.16, 1.76 | 2.44 (0.56) | 2.66 (0.68) | 0.22 (0.48) | 0.06, 0.38 |
Q5 | 2.23 (0.78) | 3.94 (0.89) | 1.71 (1.02) | 1.38, 2.04 | 2.27 (0.85) | 2.33 (0.89) | 0.06 (0.47) | −0.10, 0.21 |
Q15 | 2.48 (0.56) | 4.15 (0.87) | 1.66 (1.03) | 1.33, 1.99 | 2.5 (0.56) | 2.52 (0.84) | 0.03 (0.56) | −0.16, 0.21 |
IS, Q6-8 | 7.28 (1.70) | 11.58 (2.46)* | 4.3 (2.47) | 3.50,5.10 | 7.13 (1.76) | 7.72(1.98) | 0.58 (1.44) | 0.09,1.07 |
OF, Q9-10 | 7.84 (0.93)9( | 9.23 (1.13)* | 1.38 (1.24) | 0.98,1.78 | 7.77 (1.20) | 7.77 (1.53) | 0.0 (0.92) | −0.31,0.31 |
SD,Q11-12 | 6.35 (1.11) | 9.05 (1.36)* | 2.69 (1.73) | 2.13,3.25 | 6.47 (1.28) | 6.41 (1.5) | −0.05 (1.62) | −0.60,0.50 |
OS, Q13-14 | 5.46 (1.10) | 8.17 (1.73)* | 2.71 (1.86) | 2.10,3.31 | 5.61 (0.96) | 5.47 (1.50) | −0.14 (0.90) | −0.45,0.16 |
Total IIEF,Q1-15 | 42.56 (5.09) | 63.13 (10.06)* | 20.10 (11.08) | 16.51,23.69 | 42.54 (5.10) | 43.86 (8.45) | 1.0 (5.73) | −0.93,2.93 |